Penn Capital Management Company LLC acquired a new stake in shares of Chimerix, Inc. (NASDAQ:CMRX – Get Rating) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 847,981 shares of the biopharmaceutical company’s stock, valued at approximately $1,764,000. Penn Capital Management Company LLC owned 0.97% of Chimerix at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CMRX. Monaco Asset Management SAM acquired a new position in Chimerix during the 2nd quarter valued at approximately $3,077,000. Philosophy Capital Management LLC acquired a new position in Chimerix during the 1st quarter worth $2,888,000. State Street Corp boosted its position in Chimerix by 14.2% during the 1st quarter. State Street Corp now owns 4,561,868 shares of the biopharmaceutical company’s stock worth $20,893,000 after acquiring an additional 568,498 shares during the period. Walleye Capital LLC acquired a new position in Chimerix during the 2nd quarter worth $863,000. Finally, Pictet Asset Management SA boosted its position in Chimerix by 109.6% during the 2nd quarter. Pictet Asset Management SA now owns 662,104 shares of the biopharmaceutical company’s stock worth $1,377,000 after acquiring an additional 346,224 shares during the period. Institutional investors and hedge funds own 63.43% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on CMRX. StockNews.com upgraded Chimerix from a “hold” rating to a “buy” rating in a research report on Friday, November 4th. Capital One Financial began coverage on Chimerix in a research report on Wednesday, September 7th. They set an “overweight” rating and a $7.00 price target for the company. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Chimerix currently has a consensus rating of “Buy” and a consensus price target of $8.50.
Chimerix Stock Up 1.4 %
Insider Transactions at Chimerix
In related news, Director Fred A. Middleton bought 20,000 shares of the business’s stock in a transaction dated Thursday, September 29th. The shares were bought at an average cost of $1.86 per share, with a total value of $37,200.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $74,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 8.20% of the stock is owned by insiders.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
- Get a free copy of the StockNews.com research report on Chimerix (CMRX)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify’s Downtrend?
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.